Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Malignant Pleural Mesothelioma Clinical Trials

7 recruiting trials for Malignant Pleural Mesothelioma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
7
Total Trials
7
Recruiting Now
0
Phase 3 Trials
7
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1 / Phase 2NCT05765084

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line...

In this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen...

Sponsor: University Hospital, AntwerpEnrolling: 153 locations
RECRUITINGNCT06910449

Hemithoracic Arc Radiotherapy Post Pleural Decortication

Malignant Pleural Mesothelioma is an aggressive and refractory disease , the most aggressive treatment plan offered to these patients include trimodalitiy approach with...

Sponsor: Cairo UniversityEnrolling: 451 location
RECRUITINGNCT05655078

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).

Sponsor: University College, LondonEnrolling: 14820 locations
RECRUITINGPhase 2NCT06318286

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant...

Sponsor: Hyogo Medical UniversityEnrolling: 251 location
RECRUITINGPhase 1NCT03917043

APG-2449 in Patients With Advanced Solid Tumors

APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449...

Sponsor: Ascentage Pharma Group Inc.Enrolling: 1659 locations
RECRUITINGPhase 2NCT04400539

The IMmunotherapy Pleural 5-ALA PDT

Pilot study of the feasibility of an innovative multimodal treatment combining intrapleural photodynamic therapy with videothoracoscopy followed by adjuvant immunotherapy with...

Sponsor: University Hospital, LilleEnrolling: 201 location
RECRUITINGNCT06037941

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 207 locations

Frequently Asked Questions

There are currently 7 clinical trials for Malignant Pleural Mesothelioma, with 7 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Malignant Pleural Mesothelioma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Malignant Pleural Mesothelioma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.